Global Metastatic Melanoma Drug Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
- Published Date: 2021-04-23
- Report ID: 105695
- Pages: 118
-
Format:
Summary
World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war.
Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing global slowdown, which got aggravated due to the current Covid-19 crisis. The latter resulted in large scale disruptions in supply chains and demand resulting in cancellation of orders.
Prudent Markets analysis shows that as China started reopening its economy, world exports initially recovered across the board. But estimates of the expected recovery in 2021 are uncertain, with outcomes depending largely on the duration of the outbreak and the effectiveness of the policy responses.
This research report indicated that the global Metastatic Melanoma Drug market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. In terms of the export, China occupied more than XX % export market share in 2019, India occupied XX %. XXX is the second largest region around the world, it occupied about XX % export market share in 2019. In terms of the Local Capacity, XXX is the largest region around the world, it occupied about XX % export market share in 2019.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Metastatic Melanoma Drug Market by Prudent Markets Include
China
EU
North America
Japan
India
Southeast Asia
South America
Middle East and Africa
Competitive Analysis; Who are the Major Players in Metastatic Melanoma Drug Market
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Morphotek, Inc.
NewLink Genetics Corporation
Novartis AG
Omeros Corporation
Oncolytics Biotech Inc.
OncoSec Medical Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmis Biofarmaceutica, Lda.
Philogen S.p.A.
Plexxikon Inc.
...
Major Type of Metastatic Melanoma Drug Covered in Prudent Markets report:
AGI-134
ALT-801
ALT-803
AMG-232
Others
Application Segments Covered in Prudent Markets Market
Hospital
Clinic
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Metastatic Melanoma Drug Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
1 Market Scope
1.1 Product Details and Introduction
1.1.1 AGI-134 -Product Introduction and Major Manufacturers
1.1.2 ALT-801 -Product Introduction and Major Manufacturers
1.1.3 ALT-803 -Product Introduction and Major Manufacturers
1.1.4 AMG-232 -Product Introduction and Major Manufacturers
1.1.5 Others -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Regional Market Analysis
2.1 China Metastatic Melanoma Drug Status and Prospect (2015-2026)
2.1.1 China Metastatic Melanoma Drug Market Size and Growth Rate (2015-2026)
2.1.2 China Metastatic Melanoma Drug Local Capacity, Import, Export, Local Consumption Analysis (2015-2020)
2.2 EU Metastatic Melanoma Drug Status and Prospect (2015-2026)
2.2.1 EU Metastatic Melanoma Drug Market Size and Growth Rate (2015-2026)
2.2.2 EU Metastatic Melanoma Drug Local Capacity, Import, Export, Local Consumption Analysis (2015-2020)
2.3 USA Metastatic Melanoma Drug Status and Prospect (2015-2026)
2.3.1 USA Metastatic Melanoma Drug Market Size and Growth Rate (2015-2026)
2.3.2 USA Metastatic Melanoma Drug Local Capacity, Import, Export, Local Consumption Analysis (2015-2020)
2.4 Japan Metastatic Melanoma Drug Status and Prospect (2015-2026)
2.4.1 Japan Metastatic Melanoma Drug Market Size and Growth Rate (2015-2026)
2.4.2 Japan Metastatic Melanoma Drug Local Capacity, Import, Export, Local Consumption Analysis (2015-2020)
2.5 India Metastatic Melanoma Drug Status and Prospect (2015-2026)
2.5.1 India Metastatic Melanoma Drug Market Size and Growth Rate (2015-2026)
2.5.2 India Metastatic Melanoma Drug Local Capacity, Import, Export, Local Consumption Analysis (2015-2020)
2.6 Southeast Asia Metastatic Melanoma Drug Status and Prospect (2015-2026)
2.6.1 Southeast Asia Metastatic Melanoma Drug Market Size and Growth Rate (2015-2026)
2.6.2 Southeast Asia Metastatic Melanoma Drug Local Capacity, Import, Export, Local Consumption Analysis (2015-2020)
2.7 South America Metastatic Melanoma Drug Status and Prospect (2015-2026)
2.7.1 South America Metastatic Melanoma Drug Market Size and Growth Rate (2015-2026)
2.7.2 South America Metastatic Melanoma Drug Local Capacity, Import, Export, Local Consumption Analysis (2015-2020)
2.8 Metastatic Melanoma Drug Status and Prospect (2015-2026)
2.8.1 Metastatic Melanoma Drug Market Size and Growth Rate (2015-2026)
2.8.2 Metastatic Melanoma Drug Local Capacity, Import, Export, Local Consumption Analysis (2015-2020)
3 Global Metastatic Melanoma Drug Market Assessment by Segment
3.1 Global Metastatic Melanoma Drug Capacity and Growth Rate
3.2 Global Metastatic Melanoma Drug Sales by Type
3.3 Global Metastatic Melanoma Drug Sales Revenue by Type
3.4 Global Metastatic Melanoma Drug Consumption by Application
4 Global Metastatic Melanoma Drug Market Assessment by Regions
4.1 Global Metastatic Melanoma Drug Production Analysis and Forecast by Regions (2015-2026)
4.2 Global Metastatic Melanoma Drug Sales Analysis and Forecast by Regions (2015-2026)
4.3 Global Metastatic Melanoma Drug Sales Revenue Analysis and Forecast by Regions (2015-2026)
5 Value Chain (Impact of COVID-19)
5.1 Metastatic Melanoma Drug Value Chain Analysis
5.1.1 Upstream
5.1.2 Downstream
5.2 COVID-19 Impact on Metastatic Melanoma Drug Industry
5.2.1 Industrial Policy Issued Under the Epidemic Situation
5.3 Cost-Under the Epidemic Situation
5.3.1 Cost of Raw Material
5.4 Channel Analysis
5.4.1 Distribution Channel-Under the Epidemic Situation
5.4.2 Distributors
6 Competitive Landscape
6.1 Global Metastatic Melanoma Drug Capacity Market Share of Manufacturers (2019-2020)
6.2 Global Metastatic Melanoma Drug Sales Market Share of Manufacturers (2019-2020)
6.3 Global Metastatic Melanoma Drug Sales Revenue Market Share of Manufacturers (2019-2020)
7 Metastatic Melanoma Drug Competitive Analysis
7.1 Merck & Co., Inc.
7.1.1 Merck & Co., Inc. Company Profiles
7.1.2 Merck & Co., Inc. Product Introduction
7.1.3 Merck & Co., Inc. Metastatic Melanoma Drug Production, Revenue (2015-2020)
7.1.4 SWOT Analysis
7.2 Merck KGaA
7.2.1 Merck KGaA Company Profiles
7.2.2 Merck KGaA Product Introduction
7.2.3 Merck KGaA Metastatic Melanoma Drug Production, Revenue (2015-2020)
7.2.4 SWOT Analysis
7.3 Millennium Pharmaceuticals, Inc.
7.3.1 Millennium Pharmaceuticals, Inc. Company Profiles
7.3.2 Millennium Pharmaceuticals, Inc. Product Introduction
7.3.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Production, Revenue (2015-2020)
7.3.4 SWOT Analysis
7.4 Morphotek, Inc.
7.4.1 Morphotek, Inc. Company Profiles
7.4.2 Morphotek, Inc. Product Introduction
7.4.3 Morphotek, Inc. Metastatic Melanoma Drug Production, Revenue (2015-2020)
7.4.4 SWOT Analysis
7.5 NewLink Genetics Corporation
7.5.1 NewLink Genetics Corporation Company Profiles
7.5.2 NewLink Genetics Corporation Product Introduction
7.5.3 NewLink Genetics Corporation Metastatic Melanoma Drug Production, Revenue (2015-2020)
7.5.4 SWOT Analysis
7.6 Novartis AG
7.6.1 Novartis AG Company Profiles
7.6.2 Novartis AG Product Introduction
7.6.3 Novartis AG Metastatic Melanoma Drug Production, Revenue (2015-2020)
7.6.4 SWOT Analysis
7.7 Omeros Corporation
7.7.1 Omeros Corporation Company Profiles
7.7.2 Omeros Corporation Product Introduction
7.7.3 Omeros Corporation Metastatic Melanoma Drug Production, Revenue (2015-2020)
7.7.4 SWOT Analysis
7.8 Oncolytics Biotech Inc.
7.8.1 Oncolytics Biotech Inc. Company Profiles
7.8.2 Oncolytics Biotech Inc. Product Introduction
7.8.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Production, Revenue (2015-2020)
7.8.4 SWOT Analysis
7.9 OncoSec Medical Inc.
7.9.1 OncoSec Medical Inc. Company Profiles
7.9.2 OncoSec Medical Inc. Product Introduction
7.9.3 OncoSec Medical Inc. Metastatic Melanoma Drug Production, Revenue (2015-2020)
7.9.4 SWOT Analysis
7.10 Ono Pharmaceutical Co., Ltd.
7.10.1 Ono Pharmaceutical Co., Ltd. Company Profiles
7.10.2 Ono Pharmaceutical Co., Ltd. Product Introduction
7.10.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Production, Revenue (2015-2020)
7.10.4 SWOT Analysis
7.11 Pfizer Inc.
7.12 Pharmis Biofarmaceutica, Lda.
7.13 Philogen S.p.A.
7.14 Plexxikon Inc.
8 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
